(A) IL-36 agonists stimulate inflammatory and epithelial cells, activating the NF-κB pathway, leading to the production and secretion of inflammatory cytokines creating a feedback loop. (B) IL-36 antagonists inhibit the binding of the IL-36 co-receptor, truncating the signaling pathway. IL-1RAcP, IL-1 receptor accessory protein IL-1R3; MyD88, myeloid differentiation primary response 88; AP-1, activator protein 1; IRAKs, interleukin-1 receptor–associated kinases.